BeiGene expands US manufacturing and R&D campus in Hopewell, New Jersey

BeiGene announced the last structural steel placement at its Hopewell, New Jersey campus, a $700 million facility for commercial-stage biologic pharmaceutical manufacturing and R&D, expected to be complete in 2024.

“Adding these manufacturing and R&D capabilities in the U.S. is a major step toward fulfilling our vision to create impactful medicines that will be affordable and accessible to far more cancer patients around the world.”citybiz.co

• 1 source
• citybiz.coBeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey | citybizWilliam HarrisMar 21, 2023

Summarized from public sources; check the original articles before acting on it.